Paper Details

  1. Home
  2. Paper Details

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.

Author: BottiGerardo, ChiodiniPaolo, D'AiutoGiuseppe, De FeoGianfranco, De MaioErmelinda, Di MaioMassimo, Di RellaFrancesca, EspositoGiuseppe, GalloCiro, GravinaAdriano, LaboniaVincenzo, LandiGabriella, MorabitoAlessandro, NuzzoFrancesco, PacilioCarmen, PerroneFrancesco, PiccirilloMaria Carmela, RossiEmanuela, de MatteisAndrea

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the endocrine effects of letrozole and tamoxifen in postmenopausal patients with hormone-responsive early breast cancer. While both drugs affected hormone levels, significant differences were observed, potentially explaining the higher efficacy of letrozole compared to tamoxifen.
Paper Details　
Original Abstract of the Article :
PURPOSE We compared the endocrine effects of 6 and 12 months of adjuvant letrozole versus tamoxifen in postmenopausal patients with hormone-responsive early breast cancer within an ongoing phase III trial. PATIENTS AND METHODS Patients were randomly assigned to receive tamoxifen, letrozole, or letro...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2008.18.6213

データ提供：米国国立医学図書館（NLM）

Adjuvant Letrozole vs. Tamoxifen: Comparing Endocrine Effects in Early Breast Cancer

The landscape of breast cancer treatment is constantly evolving, with new therapies emerging to improve outcomes and minimize side effects. This study compares the endocrine effects of adjuvant letrozole and tamoxifen, two common medications used in the treatment of hormone-responsive postmenopausal women with early breast cancer. The researchers aimed to understand the hormonal differences between these two drugs and their potential implications for treatment efficacy.

The study revealed that letrozole and tamoxifen had significantly distinct endocrine effects. Letrozole, compared to tamoxifen, resulted in a greater decrease in estradiol and an increase in progesterone. Both drugs affected FSH, LH, testosterone, and DHEA-S, but the magnitude of these effects differed between the two medications. The researchers concluded that the distinct endocrine effects of letrozole, particularly its impact on estradiol and progesterone, could explain its higher efficacy compared to tamoxifen.

Letrozole's Potential Advantages in Breast Cancer Treatment

This study provides valuable insights into the endocrine effects of letrozole and tamoxifen, highlighting the potential advantages of letrozole in the treatment of hormone-responsive breast cancer. The researchers' findings suggest that letrozole's distinct impact on key hormones, particularly estradiol and progesterone, could contribute to its greater efficacy in this setting.

Understanding Endocrine Effects: A Key to Personalized Breast Cancer Treatment

This study underscores the importance of considering endocrine effects when selecting treatment strategies for breast cancer. The researchers' findings suggest that personalized treatment approaches, tailored to individual hormonal profiles, could lead to more effective and targeted therapy.

Dr. Camel's Conclusion

Just as a desert camel adapts to the harsh environment, breast cancer patients require a tailored approach that considers their unique hormonal profiles. This study sheds light on the distinct endocrine effects of letrozole and tamoxifen, offering a new perspective on personalized breast cancer treatment and a brighter path towards improved outcomes.

Date :
  1. Date Completed 2009-07-15
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19380451

DOI: Digital Object Identifier

10.1200/JCO.2008.18.6213

Related Literature

Article Analysis
・Effects of letrozole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.